.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
AstraZeneca
Daiichi Sankyo
Johnson and Johnson
Accenture
Fuji
Dow
Federal Trade Commission
Colorcon

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,132,570

« Back to Dashboard

Which drugs does patent 7,132,570 protect, and when does it expire?


Patent 7,132,570 protects NUVIGIL and is included in one NDA. There has been one Paragraph IV challenge on Nuvigil.

Protection for NUVIGIL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,132,570

Title:Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Abstract:The invention relates to a process for the preparation of crystalline forms of the optical enantiomers of modafinil, comprising stages comprising: i) dissolving one of the optical enantiomers of modafinil in a solvent other than ethanol, ii) crystallising the modafinil enantiomer, iii) recovering the crystalline form of the modafinil enantiomer so obtained. The invention also relates to a process for the preparation of the optical enantiomers of modafinil.
Inventor(s): Neckebrock; Olivier (Ponteau Combault, FR), Leproust; Pierre (Creteil, FR)
Assignee: Cephalon France (Maisons-Alfort Cedex, FR)
Application Number:10/539,918
Patent Claim Types:
see list of patent claims
Composition; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-001Jun 15, 2007ABRXYesNo7,132,570*PED► SubscribeY
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-002Mar 26, 2009DISCNYesNo7,132,570*PED► SubscribeY
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-003Jun 15, 2007ABRXYesNo7,132,570*PED► SubscribeY
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-005Mar 26, 2009ABRXYesNo7,132,570*PED► SubscribeY
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-004Jun 15, 2007ABRXYesYes7,132,570*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,132,570

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France02 16412Dec 20, 2002
PCT Information
PCT FiledDecember 18, 2003PCT Application Number:PCT/FR03/03799
PCT Publication Date:July 22, 2004PCT Publication Number: WO20/04/060858

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Boehringer Ingelheim
US Army
Accenture
Moodys
Johnson and Johnson
Queensland Health
Citi
Merck
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot